Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield NM HIV Lab Coverage Update …
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - New MexicoPolicy RPLAB065

    Human Immunodeficiency Virus (HIV)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB065 alerts

    Get alerted when Policy RPLAB065 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSNM lab reimbursement criteria for screening, confirmatory, viral load, genotyping/phenotyping, and related HIV tests; applies to providers submitting claims to Blue Cross Blue Shield - New Mexico.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyHuman Immunodeficiency Virus (HIV)
    Policy CodePolicy RPLAB065
    Change TypeCoverage exclusions and frequency language revisedcode removal
    Effective DateSep 4, 2026
    Last ReviewJan 3, 2026
    Next Review Date
    Key ActionSubmit claims with accurate documentation and valid HIPAA-approved code combinations; claims are subject to review.
    SourceLink
    POLICY UPDATE CHANGES

    Screening for HIV-1 and HIV-2 using an antibody test that does not provide rapid results and does not incorporate antigen testing is not reimbursable.

    Code 86689 was removed from the procedure code list.

    Notes and frequency language revised to reference Note 1 for repeat antibody/antigen testing and Note 3 for RNA quantification baseline considerations.

    Added Notes 1 and 2 and new items addressing PrEP-related screening and testing.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12+procedure codes enumerated (partial list shown)
    11-65age range specified for routine screening recommendations
    90dantibody/antigen repeat interval (Note 1)
    1monucleic acid testing repeat interval (Note 1)
    9numbered reimbursement items referenced

    Reimbursement and Coverage Criteria

    Extracted reimbursement criteria (summary)

    Reimbursable tests and clinical situations where testing may be covered include the following:

    ALL of the following

    • Screening

      • Initial screening for HIV infection with an antigen/antibody combination assay for individuals 11 to 65 years of age
      • Repeat antigen/antibody screening for individuals 11 to 65 years of age (see Note 1)
      • Screening with an antigen/antibody combination assay or a rapid antibody test for individuals who will begin pre-exposure prophylaxis (PrEP), who are receiving PrEP, or who have elevated risk factors (see Note 2)
    • Post-screening confirmation

      • HIV-1/HIV-2 antibody differentiation assay for individuals with a positive initial screening (see Note 1)
      • Nucleic acid testing (qualitative or quantitative) for individuals with initial positive or indeterminate screening, or when recent exposure is suspected or reported
    • Genotype / Phenotype and Viral Load

      • HIV genotyping or phenotyping prior to initiating doravirine therapy (genotyping and phenotyping required)
      • HIV genotyping or phenotyping for individuals who have failed a course of antiviral therapy, have suboptimal viral load reduction, or are noncompliant with therapy
      • Genotyping or phenotyping to guide treatment in acute or recent infection (within the last 6 months), for antiretroviral-naïve individuals entering treatment, and for pregnant individuals before initiation of antiretroviral therapy or with detectable HIV RNA loads
      • HIV phenotyping may be reimbursable for treatment-experienced individuals on failing regimens who are thought to have multidrug resistance
      • Plasma quantification of HIV-1 or HIV-2 RNA for monitoring disease progression, monitoring response to antiretroviral therapy, infants younger than 18 months born to HIV-positive mothers, and predicting maternal-fetal transmission (see Notes 1 & 3)
    ref': 'b0_0
    title": "Reimbursement criteria
    nodes

    Procedure Codes, Frequency Limits, and Notes

    Representative HIV test procedure codesmixedCovered
    86701HIV-1ANTIBODY
    86702HIV-2 ANTIBODY
    86703HIV-1/HIV-2 1 RESULT ANTBDY
    87389HIV-1 AG W/HIV-1&-2 AB AG IA
    87390HIV-1 AG IA
    87391HIV-2 AG IA
    87534HIV-1 DNA DIR PROBE
    87535HIV-1 PROBE&REVERSE TRNSCRPJ
    87536HIV-1 QUANT&REVRSE TRNSCRPJ
    87537HIV-2 DNA DIR PROBE
    1–10 of 24
    1/3
    Removed codesCPTNot Covered
    86689CPT code removed from policy (no longer reimbursable per history).
    Antibody/antigen repeat interval
    Repeat intervalNot more often than once every 90 days (see Note 1)
    Applies toAntigen/antibody combination screening for HIV (individuals 11–65 years) and repeat screening per Reimbursement Information #2
    History noteFrequency language revised in policy history; #2 now references Note 1 for repeat testing intervals
    Nucleic acid testing repeat interval
    Repeat intervalNot more often than once every month (see Note 1)
    Applies toNucleic acid testing (qualitative or quantitative) when reimbursable per Reimbursement Information #5

    Claims Submission, Documentation, and Billing Implications

    Documentation Required

    Claims submission, documentation, and claim‑review risk

    Providers must submit accurate documentation of services rendered and use valid HIPAA‑approved code combinations when billing for HIV testing. Claims are subject to code‑edit protocols and may be reviewed against Plan documents, provider contracts, medical policies, reimbursement policies, and coding software logic; upon request providers should supply additional documentation to support the claim.

    • Submit claims using valid code combinations from HIPAA‑approved code sets (CPT, HCPCS, ICD‑10, NDC, etc.).
    • Code claims according to industry standard coding guidelines (Uniform Billing Editor, AMA CPT Assistant, CMS NCCI, CCI edits).
    • Be prepared for claim review and to provide additional documentation upon request; Plan documents or provider contracts govern if conflicts arise.

    Test Definitions and Assay Types

    Antigen/antibody combination assay (initial screening)
    DefinitionAn assay that detects both HIV antigen (p24) and HIV antibodies and is used for initial screening
    Typical useInitial screening for HIV infection (reimbursable for individuals 11–65 years per Reimbursement Information #1)
    Example referencesFDA-cleared combination assays cited in References (e.g., BioPlex 2200 HIV Ag-Ab Assay)
    Nucleic acid testing (NAT)
    DefinitionNucleic acid testing (qualitative or quantitative) detecting HIV-1 or HIV-2 RNA for confirmation, suspected recent exposure, or viral load monitoring
    IndicationsMay be reimbursable for initial positive or indeterminate screening, or when recent exposure is suspected (Reimbursement Information #5)

    Policy Revisions and Effective Dates

    2026-09-04approval/updateLatest

    Added item #9 excluding reimbursement for antibody-only HIV screening tests that do not provide rapid results and do not incorporate antigen testing; removed CPT code 86689; references revised.

    2026-01-03revision

    Revised reimbursement information: removed specific 'no more than one test every 90 days' wording from item #2 and referenced Note 1; added items addressing PrEP-related screening and antibody differentiation reimbursement; adjusted monthly test language and added Notes 1 and 2; clarified antigen-only non-reimbursement.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyHuman Immunodeficiency Virus (HIV)
    Policy CodePolicy RPLAB065
    Change TypeCoverage exclusions and frequency language revisedcode removal
    Effective DateSep 4, 2026
    Last ReviewJan 3, 2026
    Next Review Date
    Key ActionSubmit claims with accurate documentation and valid HIPAA-approved code combinations; claims are subject to review.
    SourceLink
    On This Page
    Reimbursement and Coverage CriteriaProcedure Codes, Frequency Limits, and NotesClaims Submission, Documentation, and Billing ImplicationsTest Definitions and Assay TypesPolicy Revisions and Effective Dates
    History notePolicy history removed prior explicit monthly phrasing and now refers to Note 1 for NAT frequency guidance in recent edits
    Test frequency notes
    Revised frequency languagePolicy revisions adjusted prior phrasing; repeat antigen/antibody testing is referenced to Note 1 for interval guidance and NAT frequency language now references Note 1 (and Note 3 in some items) for baseline/assay-method considerations
    Notes referencedSee Note 1 for repeat-test interval limits; see Note 3 regarding assay consistency and re-establishment of baseline when methods change
    Implementation implicationRecent policy history entries added Notes 1 and 2 and altered wording of frequency limits across multiple reimbursement items
    Billing Rule

    Reimbursement and billing updates (policy history changes)

    Review the policy history and update billing practices to reflect recent reimbursement changes: an explicit non‑reimbursement of antibody‑only screening tests (added item #9) and the removal of CPT code 86689 from the procedure code list. Frequency language for repeat testing was also revised and now references policy Notes for antibody/antigen and nucleic acid testing intervals.

    • Do not bill for screening that uses an antibody test that does not provide rapid results and does not incorporate antigen testing (added as item #9).
    • Remove CPT code 86689 from billing submissions — this code was removed from the policy.
    • Note changes to repeat‑test frequency wording (e.g., antibody/antigen and NAT intervals) and follow the Notes referenced in the policy when determining allowable testing intervals.
    Assay consistencyPlasma HIV RNA levels should be measured by the same analytical method; method changes may require re-establishing baseline (Note 3)
    Antigen/antibody combination assay (reimbursement reference)
    As referenced in criteriaAntigen/antibody combination assay — assay that detects both HIV antigen (p24) and HIV antibodies used for initial screening as specified in Reimbursement Information
    Coverage contextInitial screening with an antigen/antibody combination assay may be reimbursable for individuals 11–65 years of age (Reimbursement Information #1)
    Related notesRepeat antigen/antibody screening guidance tied to Note 1 per policy revisions
    Antibody-only screening (exclusion)
    DefinitionScreening using an antibody test that does not provide rapid results and does not incorporate antigen testing is not reimbursable (added as item #9)
    ScopeThis exclusion applies to antibody-only screening tests lacking antigen detection and non-rapid-result capability as specified in Policy History entry
    Policy changeItem #9 was added in the 09/04/2026 update to explicitly exclude these antibody-only tests from reimbursement
    2025-08-08
    revision

    Added antigen/antibody combination assay language to initial screening and reinstated 'no more than one test every 90 days' wording for repeat testing; added nucleic acid testing allowance (no more than one test every month) for specific situations; removed item #6.

    2025-01-15literature_review_update

    Document updated with literature review (edits to reimbursement information noted in history).

    2023-11-01revision

    Reimbursement information revised for clarity; added items regarding HIV genotyping and phenotyping and updated references and title.

    2022-11-01creation

    Policy created (new policy established for plasma HIV-1 and HIV-2 RNA quantification and related reimbursement criteria).